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AbstrAct
Triple-negative breast cancer (TNBC) is associated with 
a high risk of recurrence and generally a bad prognosis. 
More than one-third of patients with TNBC will present 
distant metastases during the course of their disease. 
Although chemotherapy has been the main treatment 
option for metastatic TNBC for a long time, this scenario 
has changed recently with the advent of the polyadenosine 
diphosphate-ribose polymerase inhibitors (PARPis) 
for patients harbouring a mutation in the BRCA genes 
(BRCAmut) and also with the results of immunotherapy 
in patients with PD-L1-positive tumours. The present 
manuscript proposes a treatment algorithm for patients 
with metastatic TNBC based on the currently available, 
most relevant literature on the topic. For patients with 
a BRCAmut and able to tolerate chemotherapy, we 
recommend initiating treatment with platins (carboplatin/
cisplatin) and to start PARPis at disease progression. For 
patients with PD-L1-positive tumours (PD-L1 expression 
on tumour-infiltrating immune cells ≥1%), we recommend 
first-line treatment with nab-paclitaxel and atezolizumab, 
when available. In patients without a BRCA mutation and 
with PD-L1-negative tumours, we recommend single-
agent chemotherapy with taxanes (paclitaxel or docetaxel) 
as a first-line treatment. In patients with a high disease 
burden or who are very symptomatic, combinations 
such as anthracyclines plus cyclophosphamide or 
platins with taxanes are valid options. Chemotherapy 
should be maintained until the occurrence of disease 
progression or limiting toxicities. After progression to 
first-line chemotherapy, anthracyclines are an option for 
patients who received taxanes and vice versa. For patients 
who progressed to taxanes and anthracyclines, or who 
present contraindications to these agents, fluorouracil/
capecitabine, eribulin, gemcitabine, cisplatin/carboplatin, 
vinorelbine and ixabepilone are alternatives. The treatment 
of TNBC is constantly evolving, and the inclusion of 
patients in ongoing trials evaluating new targeted agents, 
immunotherapy and predictive biomarkers should be 
encouraged, in an attempt to improve metastatic TNBC 
treatment outcomes.
IntroduCtIon
Around 15% of breast cancers are classi-
fied as triple-negative (TNBC), this subtype 
being associated with an aggressive clinical 
behaviour and a poor prognosis.1 More than 
one-third of patients with TNBC will present 
distant metastases, either recurrent or de 
novo metastatic disease.1 Chemotherapy has 
been the only active treatment for metastatic 
TNBC for a long time; however, this scenario 
has recently changed with the incorpora-
tion of polyadenosine diphosphate-ribose 
polymerase inhibitors (PARPis) for patients 
harbouring BRCA mutations (BRCAmut) and 
also with the positive results of the combina-
tion of chemotherapy and immunotherapy in 
patients with PD-L1-positive tumours (PD-L1 
expression on tumour-infiltrating immune 
cells ≥1%). In the present manuscript, we will 
propose an algorithm for the first-line treat-
ment of patients with metastatic TNBC based 
on the currently available, most relevant liter-
ature on the topic, considering the advent of 
PARPis and immunotherapy (figure 1).
Chemotherapy
The most active agents in the first-line setting 
are anthracyclines and taxanes, which can 
be used either as single agents or as part of 
combination regimens.2 While combinations 
increase response rates, they are also associ-
ated with more toxicities and do not provide 
any survival advantage in comparison with 
single agents.2 Therefore, to choose between 
single agent or combinations, variables such 
as performance status, risk of adverse events, 
prior chemotherapy regimens, disease burden 
and patient preferences must be considered. 
In line with international guidelines, for most 
patients we recommend single-agent chemo-
therapy with taxanes as a first-line treat-
ment (paclitaxel or docetaxel).3 However, in 
patients with a high disease burden or who 
are very symptomatic, combinations such as 
anthracyclines with cyclophosphamide or 
platins with taxanes are valid options. Chemo-
therapy should be maintained until disease 
progression, limiting toxicities or according 
to patient preferences, and treatment pauses 
can be discussed on a case-by-case basis.3
After progression to first-line chemotherapy, 
anthracyclines, if not previously given, are an 
option for patients who received taxanes and 
vice versa.2 Several other agents are active in 
TNBC, such as fluorouracil/capecitabine, 
eribulin, gemcitabine, cisplatin/carboplatin, 
vinorelbine and ixabepilone.2 These agents 
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Figure 1 Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. 
*Defined as PD-L1 expression on tumour-infiltratingimmune cells ≥1% of the tumour area. BRCAmut, BRCA mutations; 
BRCAwt, BRCA wild type; PARPis, polyadenosine diphosphate-ribose polymeraseinhibitors; PD-L1, programmed death 
receptor ligand 1; TNBC, triple-negative breast cancer.
are appropriate options for patients who progressed 
during treatment with anthracyclines and/or taxanes, or 
for those with contraindications to anthracyclines and/
or taxanes in the first-line setting. The specific posology 
and safety profile of each agent shall be considered to 
choose the best treatment for each patient. Due to its oral 
administration, capecitabine is particularly interesting for 
patients who wish to avoid frequent visits to the hospital 
and are able to adhere to a self-administered treatment.2
patIents wIth BRCA mutatIons
A mutation in one of the BRCA genes (BRCA1 and 
BRCA2) is found in up to 20% of patients with TNBC.4 
The proteins encoded by BRCA participate in DNA 
double-strand breaks repair as part of the homologous 
recombination pathway.5 Therefore, cells harbouring 
a deleterious BRCA mutation have an impaired DNA 
repair system. Platins are alkylating agents that exert their 
effect by binding to DNA and inducing multiple single-
strand breaks, which result in apoptosis and cell death. 
The synergy of two different mechanisms that poten-
tially induce DNA damage (platins causing single-strand 
breaks and BRCAmut inefficiently repairing double-
strand breaks) is known as synthetic lethality, which is the 
rationale for a potential benefit of platins in BRCAmut 
patients. Supporting this hypothesis, in a single-arm phase 
II study with 20 patients with BRCA1mut metastatic breast 
cancer, the overall response rate with single-agent cisplatin 
(75 mg/m2 every 3 weeks for six cycles) was 80% and the 
median time to progression was 12 months.6 In the phase 
III “Carboplatin in BRCA1/2-mutated and triple-nega-
tive breast cancer BRCAness subgroups -TNT trial”, 376 
patients with metastatic TNBC were randomised 1:1 to 
receive carboplatin (area under the curve (AUC) 6 every 
3 weeks) or docetaxel (100 mg/m2 every 3 weeks). The 
objective response rates (primary endpoint of the study) 
were similar between carboplatin and docetaxel (31.4% 
vs 34.0%, respectively; p=0.66). However, in the subgroup 
of BRCAmut patients (n=43), those who received carbo-
platin presented higher response rates (68% vs 33%; 
p=0.01) and a longer median progression-free survival 
(PFS) (6.8 months vs 4.4 months; p=0.002) in comparison 
with those who received docetaxel.7
The polyadenosine diphosphate-ribose polymerase 
(PARP) is a group of proteins that have an important role 
in the repair of DNA single-strand breaks.8 By binding 
to PARP and blocking its function, PARPis interfere 
with the repair of single-strand DNA breaks; therefore, 
the concept of synthetic lethality also applies for PARPis 
in BRCAmut patients.8 In two different phase III trials, 
PARPis improved the median PFS when compared with 
chemotherapy of investigator’s choice in metastatic 
BRCAmut and human epidermal growth factor receptor 
2 (HER2)-negative patients: in the OLYMPIAD study 
(N=302), the median PFS was 7.0 months with olaparib 
(300 mg twice daily) vs 4.2 months with chemotherapy 
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(HR 0.58; 95% CI 0.43 to 0.80; p<0.001); in the EMBRACA 
study (N=431), the median PFS was 8.6 months with tala-
zoparib (1 mg once a day) vs 5.6 months with chemo-
therapy (HR 0.54; 95% CI 0.41 to 0.71; p<0.001).9 10 In 
both studies, grade ≥3 haematological toxicities were 
more frequent with PARPis, whereas non-haematolog-
ical toxicities were more frequent with chemotherapy.11 
Notably, none of these trials compared a PARPi with a 
platin-based chemotherapy, although in both studies 
olaparib and talazoparib were active in patients previ-
ously exposed to platins (in the OLYMPIAD, previous 
[neo]adjuvant platins were allowed if a minimum of 12 
months had elapsed since the last dose, whereas previous 
treatment with platins for metastatic disease was allowed 
if no disease progression occurred during therapy; in the 
EMBRACA study, previous [neo]adjuvant platins were 
allowed if the patient had a disease-free interval of at 
least 6 months after the last dose, whereas previous treat-
ment with platins for metastatic disease was allowed if no 
disease progression occurred during treatment).9 10
For patients with metastatic BRCAmut TNBC, both 
platins and PARPis are appropriate treatment options. 
Platins have a reduced cost, although they have the 
inconveniences of intravenous administration and poten-
tial adverse events such as neuropathy, nausea, ototox-
icity and haematological toxicities. On the other hand, 
PARPis have the advantage of being orally administered, 
although the elevated costs and the risks of haemato-
logical toxicities must be considered. For patients with 
BRCAmut TNBC with good performance status and no 
major uncontrolled comorbidities who are considered fit 
to tolerate chemotherapy, given the evidence that PARPis 
are active in patients previously exposed to platins, we 
recommend first-line treatment with platins (carboplatin 
or cisplatin single agent). However, starting treatment 
with PARPis is also a valid option, given there are no 
strong data to guide the sequencing of these agents. With 
the availability of new agents such as PARPis, the ideal 
treatment sequence in patients with BRCAmut TNBC 
needs to be further explored in future clinical trials.
Immunotherapy
TNBC has the highest tumour mutational burden among 
all breast cancer subtypes.12 More mutations can lead 
to the synthesis of more abnormal proteins, which may 
function as ‘neoantigens’ to be recognised by the anti-
gen-presenting cells that can ultimately start an antitu-
mour immune response.12 Supporting this hypothesis, 
tumour-infiltrating lymphocytes (TILs) are frequently 
present in TNBC samples, and increased levels of TILs 
are associated with a good prognosis.13 Therefore, TNBC 
is considered an interesting subset for the development 
of immunotherapy. In the Impassion 130 phase III study, 
902 patients with metastatic TNBC with no previous 
treatment for metastatic disease were randomised 1:1 
to receive nab-paclitaxel (100 mg/m2 on days 1, 8 and 
15 every 28 days) combined with atezolizumab (840 
mg intravenously on days 1 and 15 every 28 days) or 
placebo until disease progression or limiting toxicities. 
In the overall population, the addition of atezolizumab 
to nab-paclitaxel increased the median PFS (7.2 months 
with atezolizumab-nab-paclitaxel vs 5.5 months with place-
bo-nab-paclitaxel; HR 0.80; 95% CI 0.69 to 0.92; p=0.002), 
although it did not significantly improve overall survival 
(OS): 21.3 months with atezolizumab-nab-paclitaxel arm 
vs 17.6 months with the placebo-nab-paclitaxel (HR 0.84; 
95% CI 0.69 to 1.02; p=0.08). However, in the subgroup 
of PD-L1-positive patients (defined as PD-L1 expression 
on tumour-infiltrating immune cells ≥1% of the tumour 
area), the median PFS (7.5 months vs 5.0 months; HR 
0.62; 95% CI 0.49 to 0.78; p<0.001) and OS (25 months 
vs 15.5 months; HR 0.62; 95% CI 0.45 to 0.86) were 
improved with atezolizumab-nab-paclitaxel in compar-
ison to placebo-nab-paclitaxel.14 The frequency of grade 
≥3 adverse events was 48.7% in the atezolizumab-nab-pa-
clitaxel group and 42.2% in the placebo-nab-paclitaxel 
group, with the most common events in both groups 
being neutropaenia, peripheral neuropathy, fatigue and 
anaemia. Grade ≥3 potentially immune-related toxici-
ties occurred in 7.5% of the patients in the atezolizum-
ab-nab-paclitaxel group and in 4.3% of the patients in the 
placebo-nab-paclitaxel group.14
Although the combination of nab-paclitaxel and atezoli-
zumab is not yet available in clinical practice, it arises 
as a promising strategy to be considered for PD-L1-pos-
itive patients with metastatic TNBC. Ongoing studies 
are further evaluating new immunotherapy agents and 
potential biomarkers to predict immunotherapy response 
in patients with metastatic TNBC.15
ConClusIons
Chemotherapy has been the cornerstone in the treat-
ment of patients with metastatic TNBC for many years. 
However, potentially less toxic and more efficient strat-
egies such as PARPis and immunotherapy are changing 
this paradigm. The development of new targeted agents, 
immunotherapy and predictive biomarkers is ongoing 
with the objective to optimise the treatment of patients 
with metastatic TNBC in the forecoming years.
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